A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)
Sponsor: Arcus Biosciences, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAS9418
U.S. Govt. ID: NCT04262856
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose is to study the safety and the effect of AB122, AB154, and AB928 in participants with stage IV non-small cell lung cancer. Researchers will study the treatment response of AB122 alone as well as in combination with AB154 and AB928. There are three possible groups a participant can be randomly assigned to. Group 1 will include AB122 alone, Group 2 will include AB122 and AB154, and Group 3 will include a combination of AB122, AB154, and AB928.
This study is closed
Brian Henick, MD
Do You Qualify?
Are you at least 18 years of age? Yes No
Do you have metastatic squamous or non-squamous non-small cell lung cancer (NSCLC)? Yes No
Are you able to take oral medications? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator